Similar articles

• Prevention of adoptively transferred diabetes in nonobese diabetic mice with IL-10-transduced islet-specific Th1 lymphocytes. A gene therapy model for autoimmune diabetes.

  Moritani M, Yoshimoto K, Ii S, Kondo M, Iwahana H, Yamaoka T, Sano T, Nakano N, Kikutani H, Itakura M. Moritani M, et al. J Clin Invest. 1996 Oct 15;98(8):1851-9. doi: 10.1172/JCI118986. J Clin Invest. 1996. PMID: 8878437 Free PMC article.
• Abrogation of autoimmune diabetes in nonobese diabetic mice and protection against effector lymphocytes by transgenic paracrine TGF-beta1.

  Moritani M, Yoshimoto K, Wong SF, Tanaka C, Yamaoka T, Sano T, Komagata Y, Miyazaki J, Kikutani H, Itakura M. Moritani M, et al. J Clin Invest. 1998 Aug 1;102(3):499-506. doi: 10.1172/JCI2992. J Clin Invest. 1998. PMID: 9691086 Free PMC article.
• New insights into insulin dependent diabetes mellitus from studies with transgenic mouse models.

  Grewal IS, Flavell RA. Grewal IS, et al. Lab Invest. 1997 Jan;76(1):3-10. Lab Invest. 1997. PMID: 9010445 Review. No abstract available.
• Genes and engineered cells as drugs for type I and type II diabetes mellitus therapy and prevention.

  Giannoukakis N, Pietropaolo M, Trucco M. Giannoukakis N, et al. Curr Opin Investig Drugs. 2002 May;3(5):735-51. Curr Opin Investig Drugs. 2002. PMID: 12090547 Review.
• Oral administration of the immunodominant B-chain of insulin reduces diabetes in a co-transfer model of diabetes in the NOD mouse and is associated with a switch from Th1 to Th2 cytokines.

  Polanski M, Melican NS, Zhang J, Weiner HL. Polanski M, et al. J Autoimmun. 1997 Aug;10(4):339-46. doi: 10.1006/jaut.1997.0148. J Autoimmun. 1997. PMID: 9237797